ATEA PHARMACEUTICALS INC (AVIR) Fundamental Analysis & Valuation

NASDAQ:AVIR • US04683R1068

Current stock price

5.66 USD
-0.34 (-5.67%)
At close:
5.66 USD
0 (0%)
After Hours:

This AVIR fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. AVIR Profitability Analysis

1.1 Basic Checks

  • In the past year AVIR has reported negative net income.
  • AVIR had a negative operating cash flow in the past year.
  • AVIR had negative earnings in 4 of the past 5 years.
  • AVIR had a negative operating cash flow in each of the past 5 years.
AVIR Yearly Net Income VS EBIT VS OCF VS FCFAVIR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M 200M

1.2 Ratios

  • AVIR's Return On Assets of -50.23% is on the low side compared to the rest of the industry. AVIR is outperformed by 62.18% of its industry peers.
  • With a Return On Equity value of -57.49%, AVIR perfoms like the industry average, outperforming 46.11% of the companies in the same industry.
Industry RankSector Rank
ROA -50.23%
ROE -57.49%
ROIC N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
AVIR Yearly ROA, ROE, ROICAVIR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 -40 -60

1.3 Margins

  • AVIR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AVIR Yearly Profit, Operating, Gross MarginsAVIR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. AVIR Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, AVIR has less shares outstanding
  • Compared to 5 years ago, AVIR has less shares outstanding
  • There is no outstanding debt for AVIR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AVIR Yearly Shares OutstandingAVIR Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
AVIR Yearly Total Debt VS Total AssetsAVIR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • An Altman-Z score of 3.63 indicates that AVIR is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.63, AVIR is in the better half of the industry, outperforming 72.54% of the companies in the same industry.
  • AVIR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.63
ROIC/WACCN/A
WACCN/A
AVIR Yearly LT Debt VS Equity VS FCFAVIR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 7.82 indicates that AVIR has no problem at all paying its short term obligations.
  • AVIR has a Current ratio of 7.82. This is in the better half of the industry: AVIR outperforms 76.17% of its industry peers.
  • AVIR has a Quick Ratio of 7.82. This indicates that AVIR is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 7.82, AVIR is in the better half of the industry, outperforming 76.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.82
Quick Ratio 7.82
AVIR Yearly Current Assets VS Current LiabilitesAVIR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. AVIR Growth Analysis

3.1 Past

  • AVIR shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.00%.
EPS 1Y (TTM)3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 9.34% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y0.1%
EPS Next 2Y9.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AVIR Yearly Revenue VS EstimatesAVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2027 2028 100M 200M 300M
AVIR Yearly EPS VS EstimatesAVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. AVIR Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for AVIR. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AVIR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AVIR Price Earnings VS Forward Price EarningsAVIR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AVIR Per share dataAVIR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.34%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. AVIR Dividend Analysis

5.1 Amount

  • No dividends for AVIR!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AVIR Fundamentals: All Metrics, Ratios and Statistics

ATEA PHARMACEUTICALS INC

NASDAQ:AVIR (3/20/2026, 8:00:01 PM)

After market: 5.66 0 (0%)

5.66

-0.34 (-5.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)01-08
Earnings (Next)05-11
Inst Owners73.61%
Inst Owner Change7.11%
Ins Owners6.12%
Ins Owner Change17.12%
Market Cap450.93M
Revenue(TTM)N/A
Net Income(TTM)-158.35M
Analysts82.22
Price Target6.12 (8.13%)
Short Float %11.68%
Short Ratio14.07
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-11.77%
Min EPS beat(2)-18.09%
Max EPS beat(2)-5.44%
EPS beat(4)1
Avg EPS beat(4)-5.78%
Min EPS beat(4)-18.09%
Max EPS beat(4)4.35%
EPS beat(8)3
Avg EPS beat(8)1.86%
EPS beat(12)7
Avg EPS beat(12)6.72%
EPS beat(16)11
Avg EPS beat(16)13.26%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-4.72%
EPS NQ rev (3m)-4.72%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 1.64
EV/EBITDA N/A
EPS(TTM)-1.94
EYN/A
EPS(NY)-1.94
Fwd EYN/A
FCF(TTM)-1.7
FCFYN/A
OCF(TTM)-1.7
OCFYN/A
SpS0
BVpS3.46
TBVpS3.46
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.23%
ROE -57.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.47%
ROA(5y)-12.4%
ROE(3y)-26.96%
ROE(5y)-13.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.82
Quick Ratio 7.82
Altman-Z 3.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.5%
EPS Next Y0.1%
EPS Next 2Y9.34%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.88%
EBIT Next 3Y14.82%
EBIT Next 5YN/A
FCF growth 1Y-58.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.67%
OCF growth 3YN/A
OCF growth 5YN/A

ATEA PHARMACEUTICALS INC / AVIR Fundamental Analysis FAQ

What is the fundamental rating for AVIR stock?

ChartMill assigns a fundamental rating of 3 / 10 to AVIR.


What is the valuation status of ATEA PHARMACEUTICALS INC (AVIR) stock?

ChartMill assigns a valuation rating of 0 / 10 to ATEA PHARMACEUTICALS INC (AVIR). This can be considered as Overvalued.


How profitable is ATEA PHARMACEUTICALS INC (AVIR) stock?

ATEA PHARMACEUTICALS INC (AVIR) has a profitability rating of 0 / 10.


What is the earnings growth outlook for ATEA PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ATEA PHARMACEUTICALS INC (AVIR) is expected to grow by 0.1% in the next year.